NCT01294982View on ClinicalTrials.gov

Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Overactive Bladder
Interventions
DRUG

AOBO-001

AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily

DRUG

AOBO-001

AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily

DRUG

Placebo

Placebo Oral Capsules twice daily

Trial Locations (5)

13760

Regional Clinical Research, Inc, Endwell

20770

Myron I. Murdock M.D. LLC, Greenbelt

33409

Palm Beach Research Center, West Palm Beach

36608

Coastal Clinical Research, Mobile

67114

Heartland Research Associate, LLC, Newton

Sponsors
All Listed Sponsors
lead

American Oriental Bioengineering, Inc.

INDUSTRY

NCT01294982 - Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency | Biotech Hunter | Biotech Hunter